Europe
The tebentafusp has earned a breakthrough designation for ocular cancer. The company is planning regulatory filings in the U.S. later this year and in Europe thereafter.
The AMR Action Fund is ramping up its infrastructure – announcing yesterday that former Novartis Venture Funds Head, Henry Skinner, will take the helm as the organization’s first chief executive officer.
It was a busy week for clinical trial announcements. Here’s a look.
Novartis managed to bridge the gap between evidence of efficacy and value in this space with a variety of value-based pricing plans developed with regional payers.
Several mutations of the SARS-CoV-2 virus that causes COVID-19, which are being called variants, are increasingly being found around the world.
Biopharma and life sciences companies from around the globe provide updates on their pipelines and businesses.
The Foundation will offer funding for development of the therapy.
In 2020, Vir and GlaxoSmithKline partnered to develop strategies against COVID-19. The two companies have expanded that collaboration to include work into new treatments for influenza and other respiratory viruses.
AstraZeneca Chief Executive Officer Pascal Soriot is seeing a significant return on the fruits of his company’s labor in 2020. Soriot’s annual compensation jumped a bit from the previous year to $21.4 million.
Centessa Pharmaceuticals, based in Cambridge, Massachusetts and London, launched what it is calling a “novel asset-centric pharmaceutical company.”
PRESS RELEASES